Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A2 | P23975 | 5/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11392399 | 0.89 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11546933 | 0.89 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11383709 | 0.89 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11546513 | 0.89 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11543667 | 0.89 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11546516 | 0.89 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11392402 | 0.89 | SLC6A2 (0.64) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11546623 | 0.79 | SLC6A3 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11546627 | 0.79 | SLC6A3 (0.49) | SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL11478842 | 0.79 | SLC6A2 (0.62) | SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | PFIZER ITALIA S.R.I. (IT) | 2004-11-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235919-A1 | Phenylacetamido-thiazole derivatives, process for the preparation and their use as antitumor agents | CDK2, CDK1, CDKN1A | SLC6A2 4115/4885SLC6A4 3524/4885SLC6A3 2679/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.